4.4 Article

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 97, Issue 8, Pages 1225-1233

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2011.048215

Keywords

paroxysmal nocturnal hemoglobinuria; aplastic anemia; myelodysplastic syndrome; hematopoietic stem cell

Categories

Funding

  1. National Institutes of Health [P01CA70970, T32HL007525]
  2. ICMJE

Ask authors/readers for more resources

Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation. Many patients with aplastic anemia and myelodysplastic syndromes also harbor small populations of glycosylphosphatidylinositol-anchor deficient cells. Patients with aplastic anemia often evolve into paroxysmal nocturnal hemoglobinuria; however, myelodysplastic syndromes seldom evolve into paroxysmal nocturnal hemoglobinuria. Here, we investigate the origin and clonality of small glycosylphosphatidylinositol-anchor deficient cell populations in aplastic anemia and myelodysplastic syndromes. Design and Methods We used peripheral blood flow cytometry to identify glycosylphosphatidylinositol-anchor deficient blood cells, a proaerolysin-resistant colony forming cell assay to select glycosylphosphatidylinositol-anchor deficient progenitor cells, a novel T-lymphocyte enrichment culture assay with proaerolysin selection to expand glycosylphosphatidylinositol-anchor deficient T lymphocytes, and PIG-A gene sequencing assays to identify and analyze PIG-A mutations in patients with aplastic anemia and myelodysplastic syndromes. Results Twelve of 15 aplastic anemia patients were found to harbor a small population of glycosylphosphatidylinositol-anchor deficient granulocytes; 11 of them were found to harbor a small population of glycosylphosphatidylinositol-anchor deficient erythrocytes, 10 patients were detected to harbor glycosylphosphatidylinositol-anchor deficient T lymphocytes, and 3 of them were detected only after T-lymphocyte enrichment in proaerolysin selection. PIG-A mutation analyses on 3 patients showed that all of them harbored a matching PIG-A mutation between CFU-GM and enriched T lymphocytes. Two of 26 myelodysplastic syndromes were found to harbor small populations of glycosylphosphatidylinositol-anchor deficient granulocytes and erythrocytes transiently. Bone marrow derived CD34(+) cells from 4 patients grew proaerolysin-resistant colony forming cells bearing PIG-A mutations. No glycosylphosphatidylinositol-anchor deficient T lymphocytes were detected in myelodysplastic syndrome patients. Conclusions In contrast to aplastic anemia and paroxysmal nocturnal hemoglobinuria, where PIG-A mutations arise from multipotent hematopoietic stem cells, glycosylphosphatidylinositol-anchor deficient cells in myelodysplastic syndromes appear to arise from more committed progenitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study

David H. Henry, John Glaspy, Rosemary Harrup, Moshe Mittelman, Amy Zhou, Hetty E. Carraway, Charles Bradley, Gopal Saha, Katharina Modelska, Pamela Bartels, Robert Leong, Kin-Hung P. Yu

Summary: The study confirmed that among the three starting doses of oral roxadustat, 2.5 mg/kg showed the best performance in treating anemia, facilitating transfusion independence and reducing the need for RBC transfusions. Roxadustat administered orally thrice weekly was well-tolerated, with no fatalities or progression to acute myeloid leukemia observed.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Letter Hematology

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Simkovic, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato

BLOOD ADVANCES (2022)

Article Hematology

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero

Summary: The combination of enasidenib with azacitidine showed a 74% overall response rate in newly diagnosed mIDH2 MDS patients, while enasidenib monotherapy achieved a 35% response rate in patients after HMA failure. These findings demonstrate that enasidenib is an effective treatment option for mIDH2 MDS.

BLOOD ADVANCES (2023)

Letter Hematology

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Tariq Kewan, Waled Bahaj, Arda Durmaz, Mai Aly, Olisaemeka D. Ogbue, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski

BLOOD (2023)

Meeting Abstract Hematology

Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia

Fauzia Ullah, Danai Dima, Carmelo Gurnari, Suresh Kumar Balasubramanian, Olisaemeka Ogbue, Hussein Awada, Naomi Kawashima, Najiullah Omar, Swapna Thota, Hetty E. Carraway, Valeria Visconte, Jaroslaw P. Maciejewski

BLOOD (2022)

Meeting Abstract Hematology

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Nicholas Short, Tae Kon Kim, Rustin Lovewell, Elizabeth A. Griffiths, Hetty E. Carraway, Stephanie Zeidan, Elizabeth Knowles, Megan Nelson, Jahangheer Shaik, Chelsea Zhou, Emilia Alina Barbu, Zachary Cusumano, Subhadip Kundu, Sasan Sharee, Ron Copeland, Dallas Flies, Solomon Langermann, Han Myint, Jessica K. Altman, Farhad Ravandi

BLOOD (2022)

Article Hematology

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Amer M. Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Ades, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E. Carraway, Naval Daver, Maria Diez-Campelo, Theo de Witte, Amy E. DeZern, Fabio Efficace, Guillermo Garcia-Manero, Jacqueline S. Garcia, Ulrich Germing, Aristoteles Giagounidis, Elizabeth A. Griffiths, Robert P. Hasserjian, Eva Hellstrom-Lindberg, Marcelo Iastrebner, Rami Komrokji, Austin G. Kulasekararaj, Luca Malcovati, Yasushi Miyazaki, Olatoyosi Odenike, Valeria Santini, Guillermo Sanz, Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux

Summary: The initial response criteria developed by the International Working Group (IWG) in 2000 have limitations in their application to higher-risk MDS and their ability to fully capture the clinical benefits of novel investigational drugs. Therefore, an international panel of MDS experts used a modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results.

BLOOD (2023)

Meeting Abstract Hematology

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Julia H. Joo, Yanwen Chen, Aaron T. Gerds, Anjali Advani, Sophia R. Balderman, Hetty E. Carraway, Abhay Singh Singh, Sudipto Mukherjee

BLOOD (2022)

Meeting Abstract Hematology

Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Hussein Awada, Olisaemeka Ogbue, Ramsha Ahmed, Simona Pagliuca, Hassan Awada, Yasuo Kubota, Minako Mori, Ben Ponvilawan, Bayan Al-Share, Bhumika J. Patel, Hetty E. Carraway, Jacob Scott, Suresh Kumar Balasubramanian, Taha Bat, Yazan F. Madanat, Mikkael A. Sekeres, Torsten Haferlach, Valeria Visconte, Jaroslaw P. Maciejewski

BLOOD (2022)

Meeting Abstract Hematology

ANKRD26 Coding Variants in Myeloid Neoplasia

Teodora Kuzmanovic, Metis Hasipek, Samuel Li, Thomas Laframboise, Valeria Visconte, Sunisa Kongkiatkamon, Seth J. Corey, Sudipto Mukherjee, Anjali Advani, Aaron T. Gerds, Yogenthiran Saunthararajah, Sophia R. Balderman, Abhay Singh Singh, Hetty E. Carraway, Niroshan Nadarajah, Manja Meggendorfer, Jaroslaw P. Maciejewski, Bhumika J. Patel

BLOOD (2022)

Meeting Abstract Oncology

Age-, sex-, and race-related disparities in receipt of HypomethyLating Agents (HMA) for the treatment of myelodysplastic syndrome (MDS)

Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani, Siran M. Koroukian

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).

Farhad Ravandi-Kashani, Ashwin Kishtagari, Hetty Carraway, Emily Curran, Gary Schiller, Alex Cacovean, Bhagyashree Yadav, Thomas Butler, Jeffrey Lancet

CANCER RESEARCH (2022)

Meeting Abstract Oncology

COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma

Farhad Ravandi, Hetty Carraway, Jack Khouri, Ashwin Kishtagari, Emily Curran, Gary Schiller, Bhagyashree (Kelshikar) Yadav, Steve Morris, Alex Cacovean, Sanchita Mourya, Thomas Butler, Jeffrey Lancet

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Meeting Abstract Oncology

COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).

Farhad Ravandi, Ashwin Kishtagari, Hetty E. Carraway, Gary J. Schiller, Steve Morris, Alexandru Cacovean, Bhagyashree Kelshikar Yadav, Thomas Butler, Jeffrey E. Lancet

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Eric Laille, Jing Gong, Thomas Prebet, Daniel Lopes De Menezes, Andrew H. Wei

JOURNAL OF CLINICAL ONCOLOGY (2022)

No Data Available